HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR – Free Report) in a report issued on Thursday morning, Benzinga reports. HC Wainwright currently has a $37.00 target price on the stock.
Pharming Group Trading Up 4.8 %
Shares of Pharming Group stock opened at $8.70 on Thursday. The firm has a market capitalization of $585.89 million, a price-to-earnings ratio of -54.38 and a beta of 0.15. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The stock has a 50 day moving average of $8.05 and a 200 day moving average of $8.53.
Pharming Group (NASDAQ:PHAR – Get Free Report) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The business had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same quarter in the previous year, the company posted $0.02 earnings per share. As a group, research analysts predict that Pharming Group will post -0.15 earnings per share for the current year.
Institutional Inflows and Outflows
Pharming Group Company Profile
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Further Reading
- Five stocks we like better than Pharming Group
- Bank Stocks – Best Bank Stocks to Invest In
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Short Selling: How to Short a Stock
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a Secondary Public Offering? What Investors Need to Know
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with MarketBeat.com's FREE daily email newsletter.